Letter

Response: Tom MacDonald

Tom MacDonald replies to Marisa de Andrade

BMJ 2009; 339 doi: 10.1136/bmj.b4281 (Published 21 October 2009)
Cite this as: BMJ 2009;339:b4281

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Tom MacDonald, professor of clinical pharmacology1
  1. 1Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY
  1. tom{at}memo.dundee.ac.uk

    Thank you for allowing me to respond to Ms Andrade’s article about the Standard Care versus Celecoxib Outcome Trial (SCOT).1

    SCOT was designed by me with Professor C J Hawkey (Nottingham University) and Professor Ian Ford (Glasgow University). The protocol is the property of Dundee University (the study sponsor) and was formally approved by the European Medicines Evaluation Agency (EMEA), as well as other regulatory bodies. The aim of the study is to assess the long term drug safety of non-steroidal anti-inflammatory drugs (NSAIDs) and is funded by Pfizer USA. In general the pharmaceutical industry does not see such safety studies as attractive commercially, which is why SCOT is led by an independent investigator (me) and …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular